Gerald V Quinnan

8597658, Dec 3, 2013

Nov 12, 2008

12/742272

Gerald Quinnan - Rockville MD, US
Christopher Broder - Silver Spring MD, US

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Bethesda MD

A61K 39/00
A61K 39/21
C07K 14/00

4241881, 4241921, 530395

This invention relates to fusion polypeptides comprised of a trimerization domain fused to a non-membrane bound, non-cleaved gp160 polypeptide derived from the R2 HIV-1 Env glycoprotein and to compositions comprising the fusion polypeptides. This invention further relates to oligomers of the fusion polypeptides. This invention also relates to nucleic acids encoding the fusion polypeptides. This invention also relates to diagnostic and therapeutic methods using the fusion polypeptides. Further, this invention relates to the induction of cross-reactive neutralizing antibodies against HIV-1, and to immunogenic compositions for the prevention and treatment of infection by HIV-1.

20070009549, Jan 11, 2007

Jun 23, 2006

11/473036

Gerald Quinnan - Bethesda MD, US
Peng Zhang - Bethesda MD, US

A61K 39/12
A61K 39/00

424204100, 424229100

The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.

20080057492, Mar 6, 2008

May 12, 2003

10/513884

Gerald V. Quinnan Jr - Bethesda MD, US

C12Q 1/70
C07K 14/16

435 5, 530350

Mutations in the amino and carboxy terminal halves of HIV-1 gp120 and the carboxy terminus of gp41 are disclosed which contribute to the neutralization resistance and high infectivity phenotypes of HIV-1.

20090232830, Sep 17, 2009

Aug 29, 2005

11/661210

Gerald Quinnan - Rockville MD, US
Fatim Cham - Germantown MD, US
Guido Van De Groen - Kontich, BE

A61K 39/42
C07K 14/00
C07H 21/00
C12N 15/63
C12N 5/00
C12N 1/00
C12P 21/00
A61K 38/16
A61K 39/21
A61K 31/7052
C07K 16/00
A61P 31/18

4241601, 530350, 536 2372, 4353201, 435325, 435243, 435 691, 514 12, 4242081, 514 44 R, 5303871, 5303881

The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes.

20110293697, Dec 1, 2011

Apr 7, 2011

13/081756

Gerald V. Quinnan - Rockville MD, US
Christopher C. Broder - Silver Spring MD, US
Gerald H. Voss - Grez-Doiceau, BE
Nathalie L. Mathy - Ramillies, BE

A61K 9/127
A61P 37/04
A61P 31/18
A61K 39/21

424450, 4241881

The present invention encompasses vaccine and/or immunogenic compositions against HIV and their methods of use for the prevention and/or treatment of HIV infection and/or AIDS. The vaccine and/or immunogenic compositions may contain an isolated HIV protein or fragment thereof, an adjuvant comprising a Toll like receptor (TLR) 4 ligand, in combination with a saponin.

20120039923, Feb 16, 2012

Sep 9, 2005

11/662422

Christopher Broder - Silver Spring MD, US
Gerald Quinnan - Rockville MD, US

THE HENRY M. JACKSON FOUNDATION - Rockville MD

A61K 39/21
C12N 15/49
A61K 38/16
C12N 15/63
A61P 31/18
C12N 1/21
C12N 1/19
C12N 5/10
C07K 16/10
C07K 14/16
C12N 1/00

4241881, 530350, 536 2372, 514 38, 4242081, 4353201, 435243, 43525233, 4352542, 435348, 435325, 435358, 435357, 435352, 5303894

The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins.